UA85708C2 - Benzoxazine-containing pharmaceutical combinations for treating respiratory tract diseases - Google Patents

Benzoxazine-containing pharmaceutical combinations for treating respiratory tract diseases

Info

Publication number
UA85708C2
UA85708C2 UAA200612037A UAA200612037A UA85708C2 UA 85708 C2 UA85708 C2 UA 85708C2 UA A200612037 A UAA200612037 A UA A200612037A UA A200612037 A UAA200612037 A UA A200612037A UA 85708 C2 UA85708 C2 UA 85708C2
Authority
UA
Ukraine
Prior art keywords
benzoxazine
respiratory tract
pharmaceutical combinations
containing pharmaceutical
treating respiratory
Prior art date
Application number
UAA200612037A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Т'єрі Буісу
Інго Конетцкі
Забіне Пестель
Андреас Шнапп
Крістоф Хьонке
Філіпп Лустенбергер
Клаус Рудольф
Міхаель П. Піпер
Мішель Пере
Original Assignee
Бьорінгер Інгельхайм Інтернаціональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бьорінгер Інгельхайм Інтернаціональ Гмбх filed Critical Бьорінгер Інгельхайм Інтернаціональ Гмбх
Publication of UA85708C2 publication Critical patent/UA85708C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to novel pharmaceutical combinations containing at least one active ingredient (2) in addition to at least one, preferably one, compound of general formula (1) wherein the radicals R1, R2 and R3 have the designations cited in the patent claims and in the description. The invention also relates to a method for producing said combinations and to the use thereof as medicaments. (1)
UAA200612037A 2004-04-22 2005-04-18 Benzoxazine-containing pharmaceutical combinations for treating respiratory tract diseases UA85708C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004019540A DE102004019540A1 (en) 2004-04-22 2004-04-22 Composition, useful for treatment of e.g. inflammatory and obstructive respiratory complaint, sinus rhythm in heart in atrioventricular block and circulatory shock, comprises 6-hydroxy-4H-benzo1,4oxazin-3-one derivatives and other actives

Publications (1)

Publication Number Publication Date
UA85708C2 true UA85708C2 (en) 2009-02-25

Family

ID=35456100

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200612037A UA85708C2 (en) 2004-04-22 2005-04-18 Benzoxazine-containing pharmaceutical combinations for treating respiratory tract diseases

Country Status (3)

Country Link
CN (1) CN101035540A (en)
DE (1) DE102004019540A1 (en)
UA (1) UA85708C2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
DE102005035891A1 (en) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
KR101360803B1 (en) 2005-08-15 2014-02-11 베링거 인겔하임 인터내셔날 게엠베하 Method for producing betamimetics
EP1986644A1 (en) * 2006-02-16 2008-11-05 Boehringer Ingelheim International GmbH Drug combinations for the treatment of respiratory tract diseases
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
CN102838599A (en) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 Polymorphs
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
UY30542A1 (en) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int AEROSOL FORMULATION FOR INHALATION OF BETA AGONISTS
PE20091730A1 (en) 2008-04-03 2009-12-10 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
KR20200118243A (en) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
BRPI0919288A2 (en) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh combination therapy for treatment of diabetes and related conditions.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (en) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх SALT FORMS OF ORGANIC COMPOUND
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (en) 2010-11-15 2013-03-27 Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (en) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Medical use of a DPP-4 inhibitor
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN118903009B (en) * 2024-10-11 2025-01-21 江苏长泰药业股份有限公司 Sodium pyruvate aerosol for regulating respiratory microecology and preparation method and application thereof

Also Published As

Publication number Publication date
CN101035540A (en) 2007-09-12
DE102004019540A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
SG148177A1 (en) Novel cis-imidazolines
TW200615266A (en) Organic compounds
TW200738242A (en) Dihydropteridinones in the treatment of respiratory diseases
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2004037773A8 (en) Phenethanolamine derivative for the treatment of respiratory diseases
WO2004037768A3 (en) Phenethanolamine derivatives
TW200616974A (en) Chemical compounds
UA83233C2 (en) Substituted 2-aminotetralin for the treatment of depression
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2005111002A3 (en) Substituted cycloalkyl derivatives for use in the treatment of respiratory diseases
WO2004037789A3 (en) Methylene urea derivatives as raf-kinase inhibitors
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
UA86977C2 (en) Hydantoin derivatives for the treatment of obstructive airway diseases
UA85707C2 (en) Benzoxazines for treating respiratory tract diseases
MX2007003031A (en) Heteroaryl compounds for use as betamimetics in the treatment of respiratory diseases.
TW200621259A (en) Chemical compounds
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2005040171A8 (en) Pyrazolo and imidazo-pyrimidine derivatives
WO2003087049A3 (en) Pharmaceutical combinations containing heterocyclic compounds and a novel anticholinergic agent
MXPA05010020A (en) Oxamide derivatives useful as raf-kinase inhibitors.
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
MXPA05005790A (en) Aminoalkoxyindoles as 5-ht6-receptor ligands for the treatment of cns-disorders.